Compare MHO & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MHO | VKTX |
|---|---|---|
| Founded | 1976 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 4.0B |
| IPO Year | 1995 | 2014 |
| Metric | MHO | VKTX |
|---|---|---|
| Price | $124.58 | $25.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 21 |
| Target Price | ★ $170.67 | $94.50 |
| AVG Volume (30 Days) | 182.1K | ★ 7.9M |
| Earning Date | 10-21-2026 | 10-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.57 | N/A |
| Revenue | ★ $4,417,781,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.09 | N/A |
| P/E Ratio | $22.62 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $116.78 | $25.28 |
| 52 Week High | $163.66 | $43.15 |
| Indicator | MHO | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 30.22 | 35.80 |
| Support Level | $118.54 | N/A |
| Resistance Level | $127.01 | $34.00 |
| Average True Range (ATR) | 3.44 | 1.46 |
| MACD | -0.49 | -0.49 |
| Stochastic Oscillator | 17.64 | 1.63 |
M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.